Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Iloperidone
Drug ID BADD_D01134
Description Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.
Indications and Usage Treatment of acute schizophrenia.
Marketing Status Prescription
ATC Code N05AX14
DrugBank ID DB04946
KEGG ID D02666
MeSH ID C081732
PubChem ID 71360
TTD Drug ID D0M8VE
NDC Product Code 51672-4178; 51672-4181; 43068-112; 43068-108; 43068-902; 43068-106; 51672-4183; 66499-0042; 46016-1332; 43068-104; 66022-0115; 63285-756; 43068-101; 50379-0006; 63285-755; 43068-901; 43068-903; 66499-0067; 51672-4180; 51672-4213; 43068-102; 51672-4179; 51672-4182; 51672-4184; 43068-110; 43068-113
Synonyms iloperidone | Fanapt | HP 873 | HP-873 | Zomaril
Chemical Information
Molecular Formula C24H27FN2O4
CAS Registry Number 133454-47-4
SMILES CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Constipation07.02.02.0010.000602%
Death08.04.01.001--
Dehydration14.05.05.001--
Delirium19.13.02.001--
Delusion19.10.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.0030.001806%
Dry eye06.08.02.001--
Dry mouth07.06.01.0020.000903%
Dry throat22.02.05.004; 07.06.01.005--Not Available
Duodenal ulcer07.04.02.002--
Dyskinesia17.01.02.006--
Dyspnoea22.02.01.004; 02.01.03.002--
Dyspnoea exertional22.02.01.005; 02.01.03.003--Not Available
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Ejaculation failure21.03.01.003--Not Available
Electrocardiogram QT prolonged13.14.05.0040.001505%
Endocrine disorder05.09.01.001--Not Available
Enuresis19.07.04.001; 20.02.02.003--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Extrapyramidal disorder17.01.02.0070.000602%
Eye disorder06.08.03.001--Not Available
Eye swelling06.08.03.003--Not Available
Eyelid oedema10.01.05.001; 06.04.04.004; 23.04.01.0030.000602%Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Gait disturbance17.02.05.016; 08.01.02.0020.000903%
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages